Nanocage-tethered Polymeric Hybridome for pDNA Delivery: A Revolutionary Approach for Treatment of Glioblastoma
Journal of Cancer Biomoleculars and Therapeutics · 2025
DOI: 10.62382/jcbt.v2i1.48 ↗Abstract
Glioblastoma, a highly aggressive form of brain cancer, poses a formidable challenge in the field of oncology due to its resistance to conventional therapies and limited drug delivery options. This abstract highlights a groundbreaking strategy for combating glioblastoma by introducing a novel nanocage-tethered polymeric hybridome for the efficient and targeted delivery of plasmid DNA (pDNA). Our innovative approach combines the benefits of nanotechnology and polymer science to create a hybrid system capable of overcoming the inherent obstacles faced in glioblastoma treatment. The nanocage, acting as a carrier, not only ensures the protection and stability of the pDNA payload but also offers precise targeting capabilities. The tethering of polymers to the nanocage further enhances the biocompatibility, cellular uptake, and controlled release of pDNA. This nanocage-tethered polymeric hybridome has demonstrated exceptional potential in preclinical studies. It exhibits an unprecedented ability to penetrate the blood-brain barrier, specifically target glioblastoma cells, and efficiently deliver therapeutic pDNA payloads. Moreover, this approach minimizes off-target effects and reduces systemic toxicity, thus enhancing the safety profile. In conclusion, the development of the nanocage-tethered polymeric hybridome represents a paradigm shift in glioblastoma therapy.
EUVIMED